Mayo Clinic
Mayo Clinic
Phoenix, Arizona, United States2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Digestive System Diseases, Digestive System Neoplasms, Malignant Peripheral Nerve Sheath Tumors, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, Thoracic Neoplasms, adenoma, bronchial neoplasm, bronchogenic carcinoma, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fibrosarcoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, non-small cell lung carcinoma, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, peripheral nervous system disorder, peripheral nervous system neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma | Recruiting | Phase 1 | 2026-09-02 | NCT05245500 | |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder | Recruiting | Phase 3 | 2026-05-13 | NCT05677971 |